SCHEMBL17688782

SCHEMBL17688782

Clc1cc(NCCCN2CCCCC2)c2ccccc2n1

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 16/20 0.68
HRH3 Q9Y5N1 2/20 0.65
SMARCA2 P51531 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5276042 0.96 HRH3 (0.65) ACP1HRH3SMARCA2
SCHEMBL491641 0.85 ACP1 (0.70) ACP1HRH3SMARCA2
SCHEMBL20552777 0.85 ACP1 (0.58) ACP1HRH3
SCHEMBL20552916 0.85 ACP1 (0.58) ACP1HRH3
SCHEMBL2512341 0.82 ACP1 (0.55) ACP1
SCHEMBL20552524 0.82 HRH3 (0.55) ACP1HRH3
SCHEMBL20553037 0.82 HRH3 (0.55) ACP1HRH3
SCHEMBL5281506 0.82 ACP1 (0.66) ACP1HRH3
SCHEMBL17688792 0.81 ACP1 (1.00) ACP1SMARCA2
SCHEMBL491669 0.81 HRH3 (0.66) ACP1HRH3SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11220486-B2 Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) 2022-01-11 US disclosed
US-11220486-B2 Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) 2022-01-11 US disclosed
EP-3206689-B1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF LA JOLLA INST OF ALLERGY & IMMUNOLOGY (US) 2021-12-08 EP disclosed
EP-3206689-B1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF LA JOLLA INST OF ALLERGY & IMMUNOLOGY (US) 2021-12-08 EP disclosed
US-20200290977-A1 Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY 2020-09-17 US disclosed
US-20200290977-A1 Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY 2020-09-17 US disclosed
US-10626094-B2 Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2020-04-21 US disclosed
US-10626094-B2 Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2020-04-21 US disclosed
US-20170247340-A1 Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY 2017-08-31 US disclosed
US-20170247340-A1 Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY 2017-08-31 US disclosed
US-20170247340-A1 Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY 2017-08-31 US disclosed
EP-3206689-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF La Jolla Institute of Allergy & Immunology (US) 2017-08-23 EP disclosed
WO-2016061280-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) 2016-04-21 WO disclosed
WO-2016061280-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) 2016-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220486-B2 Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof ACP1, PTPRCAP, PTPA ACP1 1/4885HRH3 4805/4885SMARCA2 3356/4885
US-10626094-B2 Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof ACP1, PTPRCAP, PTPA ACP1 1/4885HRH3 4805/4885SMARCA2 3356/4885
US-20200290977-A1 Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof ACP1, PTPRCAP, PTPA ACP1 1/4885HRH3 4805/4885SMARCA2 3356/4885
US-20170247340-A1 Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof ACP1, PTPRCAP, PTPA ACP1 1/4885HRH3 4805/4885SMARCA2 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.